Drug Trial Radar · NCT03098615
Study Evaluating the Effect of Jublia on Dermatophytomas
Last checked: Nov 20, 2026Latest source record: Dec 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Sep 2015
Primary completion
May 2017
Study completion Jul 2018
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.
Conditions
- Onychomycosis
- Dermatophytosis
Interventions
Jublia (Efinaconazole 10% Topical Solution)Drug
Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO)Time frame: week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Kirklin Clinic
Birmingham, Alabama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.